Heart-homing peptide

Heart-homing peptide 是一种序列为 CRPPR 的心脏靶向肽,可介导心脏内皮靶向并在心脏组织中富集,介导脂质体和外泌体货物跨心脏内皮进入间质组织,增强外泌体在心脏中的富集,抑制 GP130-STAT3/ERK1/2/AKT 通路,并在小鼠缺血/再灌注、心肌梗死和肥大部位富集,可用于心血管疾病的研究。
产品编号: MS-N74180 CAS No.: 876460-72-9 分子式: C25H45N11O6S 分子量: 627.76
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Heart-homing peptide 是一种序列为 CRPPR 的心脏靶向肽,可介导心脏内皮靶向并在心脏组织中富集,介导脂质体和外泌体货物跨心脏内皮进入间质组织,增强外泌体在心脏中的富集,抑制 GP130-STAT3/ERK1/2/AKT 通路,并在小鼠缺血/再灌注、心肌梗死和肥大部位富集,可用于心血管疾病的研究。

生物实验数据

生物活性 Heart-homing peptide is a cardiac-targeting peptide with the sequence CRPPR that mediates cardiac endothelial targeting and enriches in cardiac tissue, mediates the transport of liposomal and exosomal cargo across the cardiac endothelium into the interstitial tissue, enhances exosomal enrichment in the heart, inhibits the GP130-STAT3/ERK1/2/AKT pathway, and enriches at sites of ischemia/reperfusion, myocardial infarction, and hypertrophy in mice, making it useful for research on cardiovascular diseases.
体内研究
(In Vivo)

Heart-homing peptide-exposed liposomes (7-60 mg/kg;静脉注射;单次给药) 可高效地将载药递送至完整小鼠心脏内皮细胞内,在单次静脉注射 20 mg/kg 剂量时观察到药物的峰值蓄积与转运,给药 30 分钟内心脏组织的荧光强度较非靶向脂质体升高 47 倍。
Heart-homing peptide-exosomes (4 mg/kg;静脉注射;每 3 天 1 次;共 7 次) 可在小鼠心脏中优先富集,显著改善心脏功能,减轻左心室肥厚与纤维化,并在主动脉缩窄 (TAC) 诱导的心肌肥厚模型中使肥厚信号分子恢复正常,其作用由 miRNA-148a 依赖的 GP130-STAT3/ERK1/2/AKT 通路抑制介导。

Animal Model: FVB (2-month old, male, 20-25 g)
Dosage: 7 mg/kg; 20 mg/kg; 60 mg/kg
Administration: i.v.; single dose
Result: Achieved 47-fold greater fluorescence in cardiac tissue surrounding vascular lumens than non-targeted liposomes and 64-fold greater than free dye within 30 minutes of 20 mg/kg injection.
Increased tissue, endothelial, and punctate fluorescence intensities from 7 mg/kg to 20 mg/kg, with no further increase at 60 mg/kg, indicating saturation of accumulation and trans-endothelial transport.
Maintained cardiac fluorescence intensity at ~40% of the 30-minute value at 24 hours post-injection, which was significantly greater than control groups.
Detected fluorescence above non-treated controls in 37.0% of endothelial (CD31+) cells, 0.63% of cardiomyocytes (MF20+), and 5.3% of fibroblasts (Thy1.1+) at 4 hours post-injection of 60 mg/kg liposomes.
Detected fluorescence above non-treated controls in 29.1% of endothelial (CD31+) cells, 0.80% of cardiomyocytes (MF20+), and 4.0% of fibroblasts (Thy1.1+) at 12 hours post-injection of 60 mg/kg liposomes.
Animal Model: C57BL/6 (10-week-old male, TAC-induced pressure overload)
Dosage: 4 mg/kg
Administration: i.v.; every third day; 7 doses total
Result: Accumulated at nearly double the mean fluorescence intensity in mouse hearts 24 hours post-single intravenous administration compared to non-targeted exosomes.
Significantly ameliorated TAC-induced reductions in left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) at days 28 and 42 post-TAC, and significantly improved left ventricular end-systolic volume (LVV.s), diastolic left ventricular anterior wall thickness (LVAW.d), systolic left ventricular anterior wall thickness (LVAW.s), and left ventricular mass compared to PBS controls.
Reversed TAC-induced mean arterial blood pressure elevation from 116.70 mmHg to 92.37 mmHg.
Significantly reduced serum levels of angiotensin II (Ang II) and N-terminal pro B-type natriuretic peptide (NT-proBNP), and lung wet/dry weight ratio compared to PBS controls.
Significantly reduced TAC-induced increases in heart/body weight ratio, heart weight/tibial length ratio, and relative cardiomyocyte surface area (increased by 30% in PBS-treated TAC mice).
Significantly reduced TAC-induced upregulation of hypertrophic marker genes Acta1, Nppa, Nppb, and the Myh7/Myh6 ratio, and significantly decreased perivascular and myocardial interstitial fibrosis from 19.49% and 16.88% in PBS-treated TAC mice to 2.43% and 1.13%.
Significantly reduced TAC-induced upregulation of hypertrophy-associated proteins β-MHC, BNP, GP130, p-ERK1/2, p-AKT, and p-STAT3 in ventricular tissues.
Restored TAC-induced reduction in cardiac miRNA-148a levels to 252.30% of sham levels (vs.
66.83% in PBS-treated TAC mice).

化学信息

分子量 627.76
分子式 C25H45N11O6S
CAS No. 876460-72-9

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础